Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Inflammatory Bowel Disease Treatment Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.
Recent market analysis forecasts an impressive growth trajectory for the global inflammatory bowel disease treatment sector, with expectations to achieve a robust compound annual growth rate (CAGR) of 5.84% in the period extending from 2024 to 2034.
The study cited an estimated market size of USD 26.65 billion in 2023, with figures potentially ascending to USD 49.76 billion within the predicted timeline, bolstered by factors such as the enhancing early diagnostic techniques and surging number of treatment options available for IBD (Inflammatory Bowel Disease).
Inflammatory Bowel Disease Treatment Market Analysis & Forecast by Drug Class
- Corticosteroids
- TNF Inhibitors
- Anti-Integrin
- ASA Drugs
- JAK Inhibitors
- IL Inhibitors
- Others
The growth indicators highlight significant investments in innovative product developments, surge in research and development initiatives, and an increase in drug approvals from regulatory bodies, playing pivotal roles in fueling market expansion.
Key Market Segment Insights
TNF inhibitors are leading the drug class segment, while the JAK inhibitors category is anticipated to be the fastest-growing sector due to the ease of oral administration and swift action.
The report reveals that injectables maintain their preeminence in the market, with heightened interest in biologics marking significant progress in the treatment of Crohn's disease and ulcerative colitis. Parallelly, oral administration routes are projected to show the fastest CAGR impelled by the convenience of self-medicating and widespread availability of IBD medications.
In terms of indications, Crohn's disease commanded the major revenue share, while the ulcerative colitis treatment segment is expected to rise rapidly, influenced by the increased approvals for drugs aimed at the malady.
Distribution channels also play a crucial role, with hospital pharmacies constituting the largest segment due to the supportive reimbursement scenarios. At the same time, retail pharmacies are anticipated to experience considerable growth reflecting the shift towards online pharmacy services.
Regional Outlook
North America's IBD treatment market is predicted to dominate revenue shares, driven by favorable reimbursement frameworks and an increasing patient pool requiring treatment for ulcerative colitis and Crohn's disease. It is further backed by collaborative efforts among pharmaceutical giants. Conversely, the Asia Pacific region is poised for the most brisk expansion, propelled by elevated healthcare investments and a burgeoning number of patients seeking treatment.
These findings are drawn from a comprehensive industry report offering a granular analysis of drug classes, administration routes, indications, distribution channels, and regional market performances.
The report delves into the dynamics influencing the burgeoning treatments for conditions within the IBD spectrum, encompassing both ulcerative colitis and Crohn's disease, and assessing the impact of various drugs on the global market landscape.
By providing essential insights into the swift development of novel therapies and examining the substantial growth in patient populations undergoing treatment, the analysis serves as a vital tool for stakeholders in the healthcare and pharmaceutical sectors.
The extensive report is now accessible, furnishing stakeholders and industry leaders with pivotal data to drive informed decision-making and strategic planning.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value (USD) in 2023 | $26.65 Billion |
| Forecasted Market Value (USD) by 2034 | $49.76 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
Companies Mentioned
- Biogen
- AbbVie Inc
- Lilly
- UCB S.A.
- Pfizer Inc
- Johnson & Johnson Services Inc
- CELLTRION INC.
- Novartis AG
- Merck & Co. Inc.
- Takeda Pharmaceutical Company Limited
For more information about this report visit https://www.researchandmarkets.com/r/qckskr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
